Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020
Seres Therapeutics (Nasdaq: MCRB) announced a conference call on November 9, 2020, at 8:30 a.m. ET to discuss Q3 2020 results and provide a business update. The SER-109 program has achieved significant clinical milestones, including Breakthrough Therapy and Orphan Drug designations from the FDA, targeting recurrent C. difficile infections. Additional programs like SER-287 and SER-401 are in various stages of clinical evaluation, with FDA designations indicating potential for innovation in microbiome therapeutics.
- SER-109 program received Breakthrough Therapy and Orphan Drug designations.
- SER-109 achieved positive pivotal clinical results, indicating strong market potential.
- SER-287 program has Fast Track and Orphan Drug designations, advancing in Phase 2b study.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today announced that management will host a conference call and live audio webcast on November 9, 2020 at 8:30 a.m. ET to discuss third quarter 2020 results and provide a general business update.
To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 1038426. To join the live webcast, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.
